{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "AXGN",
  "name": "Axogen, Inc.",
  "url": "https://frontierpicks.com/dossiers/AXGN/",
  "json_url": "https://frontierpicks.com/dossiers/AXGN.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Axogen's nerve-repair revenue is growing above 25% with Avance coverage near universal, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether organic revenue reaches the at least $283 million guided.",
  "invalidation_trigger": "A daily close below $42.50, the price of Axogen's September 2026 public offering. 2026 revenue excluding BioCircuit under $283 million, or full-year gross margin under 73%, would also end the case.",
  "catalyst_date": "2026-11-09",
  "pick": {
    "id": "P-2026-11-06-AXGN",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-11-06",
    "open_close": 50.02,
    "kill_level": 42.5,
    "kill_basis": "daily",
    "horizon_end": "2027-02-09",
    "last_date": "2026-11-06",
    "last_close": 50.02,
    "return_pct": 0,
    "spy_return_pct": 0,
    "excess_pp": 0,
    "kill_distance_pct": 17.69411764705884,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Axogen's 10-Q says it depends on a leased facility in Dayton, Ohio, for processing, so a disruption there would affect supply.",
    "One contract partner is the exclusive manufacturer or distributor for several Axoguard products, under agreements running to 2030, per the 10-Q."
  ],
  "source_links": [
    {
      "title": "Axogen, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000106/ex991axgnearningsreleaseda.htm",
      "date": null
    },
    {
      "title": "Axogen, Inc. - Form 10-Q - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000108/axgn-20260930.htm",
      "date": null
    },
    {
      "title": "Axogen Soars 29% on Q3 Beat, Lifts 2026 Revenue Guidance to at Least $290 Million",
      "url": "https://www.tikr.com/blog/axogen-soars-29-on-q3-beat-lifts-2026-revenue-guidance-to-at-least-290-million",
      "date": null
    },
    {
      "title": "Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences",
      "url": "https://ir.axogeninc.com/news-events/press-releases/detail/1011/axogen-inc-to-participate-in-multiple-upcoming-investor-conferences",
      "date": null
    },
    {
      "title": "Axogen, Inc. - Form 4 - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0000805928/000080592826000099/wk-form4_1786565598.xml",
      "date": null
    }
  ],
  "body_markdown": "## Current Thesis\nAxogen's nerve-repair revenue is growing above 25% with commercial coverage for its Avance nerve graft near universal, which gives the shares a modest edge over the S&P 500 for the next three months. The fourth-quarter 2026 report settles it: it shows whether revenue excluding the BioCircuit acquisition reaches the at least $283 million guided for 2026 and whether gross margin holds at 73% or better.\n\nOn 2026-10-28 Axogen reported third-quarter revenue of $75.8 million, up 26.2% from $60.1 million a year earlier. Benzinga put the estimate at $73.2 million. The company raised its 2026 revenue guidance to at least $290 million from at least $279 million, and TIKR reported a 29% gain in the shares that day.\n\nThe narrative is accelerating: six brokers raised price targets on 2026-10-29, and the company holds a call on its prostate opportunity on 2026-11-09. The main constraint is price. TIKR put the shares at roughly 83 times forward earnings after the 2026-10-28 jump, so a slower quarter would have little valuation support.\n\n## Bull Case\n- **Growth is broad and organic.** Third-quarter growth of 26.2% came before BioCircuit closed on 2026-10-01, and nine-month revenue reached $207.0 million against $165.3 million a year earlier (Form 8-K, 2026-10-28). The company cites growth of more than 20% in account productivity across Extremities, Oral Maxillofacial & Head and Neck, and Breast.\n- **The coverage gap has nearly closed.** Positive decisions from Elevance and Aetna took commercial coverage for Avance to about 96% of US covered lives (Form 8-K, 2026-10-28).\n- **New surgical markets are opening.** TIKR reported Breast revenue growth above 50% in the third quarter. Prostate market development begins in 2027, and TIKR reports the company sizes that US opportunity at $754 million ahead of the 2026-11-09 call.\n- **Cash generation has turned positive.** Free cash flow was $18.9 million for the nine months to 2026-09-30 against negative $5.9 million a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin rose to 17.7% in the third quarter from 15.4%.\n- **Analysts moved targets up together.** On 2026-10-29 Benzinga listed targets of $60 from Canaccord Genuity, Barclays and Truist, and $56 from Leerink, Wells Fargo and HC Wainwright. Leerink's target rose from $52.\n\n## Bear Case\n- **Valuation leaves little room.** TIKR's estimate of roughly 83 times forward earnings on 2026-10-28 compares with about 65 times before the report. That multiple rests on growth continuing above 25%.\n- **Gross margin is moving down.** Third-quarter gross margin fell to 74.8% from 76.6%, which the 10-Q attributes mainly to higher product costs. Guidance of at least 73% for 2026 leaves room for further decline.\n- **Reported profit trails adjusted profit.** Third-quarter net income was $2.3 million against adjusted net income of $13.1 million, with stock-based compensation of $8.8 million. Operating income fell to $1.0 million from $1.9 million.\n- **Share issuance has been heavy.** Axogen sold 4,600,000 shares at $31.00 in January 2026 and 5,646,500 at $42.50 in September 2026 (10-Q).\n- **BioCircuit must earn its price.** Axogen paid $200 million in cash, before adjustments, on 2026-10-01 for the developer of NerveTape. Guidance credits it with at least $7 million of 2026 revenue, and the company expects about $5 million more in transaction expenses in the fourth quarter.\n- **Avance's approval carries a condition.** The Food and Drug Administration approved the Avance Biologics License Application on 2025-12-03. The 10-Q says continued approval depends on confirmatory studies verifying clinical benefit.\n\n## Setup & Price Structure\nThe shares closed at $48.75 on 2026-11-05, 5.8% below the 52-week high of $51.73 on adjusted daily closes. The three-month change is only 1.1%. A 29% one-day gain inside that figure means the shares had fallen before the report, so the October jump mainly restored earlier levels.\n\nCrowding signs are visible. The 14-day relative strength index, a momentum gauge on which readings above 70 are commonly called overbought, stood at 82.5 on 2026-11-05. SEC Form 4 filings show general counsel Marc Began sold 67,500 shares at $47.345 on 2026-08-10 after exercising options at $8.16, under a Rule 10b5-1 trading plan.\n\nThe September offering price of $42.50 is the clearest reference below the market. The brokers' $56 to $60 targets sit above the 52-week high.\n\n## Catalyst Calendar (next 30 days)\n- **2026-11-09: prostate investor call.** It shows how much spending and time Axogen attaches to a market it plans to start building in 2027.\n- **2026-11-11, 10:00 AM ET: Canaccord Genuity MedTech forum fireside chat.** This is the first public management appearance listed after the prostate call.\n- **2026-11-17, 8:30 AM ET: Jefferies Global Healthcare Conference fireside chat, London.** Management may comment on BioCircuit integration and fourth-quarter trends.\n- **2026-12-02, 8:00 AM ET: Piper Sandler Healthcare Conference presentation.** This is the last scheduled appearance in the window.\n- **~2027-02-25, est.: fourth-quarter 2026 report.** This falls outside the 30 days, but the case turns on it. Nine-month revenue of $207.0 million and guidance of at least $290 million set the bar.\n\n## What Would Change Our Mind\nThe case breaks if 2026 revenue excluding BioCircuit falls under $283 million, or if full-year gross margin falls under 73%. Either would show that demand or product costs are worse than management guided on 2026-10-28. Negative full-year free cash flow would also break it, since the company guided to a positive figure.\n\nA reversal of commercial coverage by a major payer, or an adverse result from the Avance confirmatory studies, would weaken the growth argument directly. A prostate plan on 2026-11-09 that requires spending heavy enough to reverse the 17.7% adjusted EBITDA margin would weaken the profit argument.\n\nOn price, a daily close below $42.50 would end the thesis. That level is the price investors paid in the September 2026 offering, and a close under it would give back much of the post-report gain.\n\n## Correlation Notes\nAxogen's main drivers are company-specific: payer coverage, surgeon adoption and account productivity. The medtech and diagnostics group, including Enovis, Myriad Genetics, OrthoPediatrics, Dexcom and Danaher, is maturing: attention has slowed since the week of 2026-10-18.\n\nThe view is that this cooling raises the bar without deciding the outcome, because the October report is Axogen's own evidence. That view would be wrong if the shares closed below $42.50 alongside a group decline with no Axogen-specific news. No measured correlation figure supports this section.",
  "first_seen": "2026-11-06",
  "last_analyzed": "2026-11-06T12:15:04+00:00",
  "last_synthesized": "2026-11-06",
  "last_update_source": "research_universe",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}